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Glucocorticoids limit acute lung inﬂammation in
concert with inﬂammatory stimuli by induction of
SphK1
Sabine Vettorazzi1,2, Constantin Bode3, Lien Dejager4, Lucien Frappart5, Ekaterina Shelest6, Carina Klaen7,
Alpaslan Tasdogan8, Holger M. Reichardt7, Claude Libert4, Marion Schneider9, Falk Weih2,
N. Henriette Uhlenhaut10, Jean-Pierre David11, Markus Gra¨ler3,12, Anna Kleiman2,12,* & Jan P. Tuckermann1,2,*
Acute lung injury (ALI) is a severe inﬂammatory disease for which no speciﬁc treatment
exists. As glucocorticoids have potent immunosuppressive effects, their application in ALI is
currently being tested in clinical trials. However, the beneﬁts of this type of regimen remain
unclear. Here we identify a mechanism of glucocorticoid action that challenges the long-
standing dogma of cytokine repression by the glucocorticoid receptor. Contrarily, synergistic
gene induction of sphingosine kinase 1 (SphK1) by glucocorticoids and pro-inﬂammatory
stimuli via the glucocorticoid receptor in macrophages increases circulating sphingosine
1-phosphate levels, which proves essential for the inhibition of inﬂammation. Chemical or
genetic inhibition of SphK1 abrogates the therapeutic effects of glucocorticoids. Inﬂammatory
p38 MAPK- and mitogen- and stress-activated protein kinase 1 (MSK1)-dependent pathways
cooperate with glucocorticoids to upregulate SphK1 expression. Our ﬁndings support a critical
role for SphK1 induction in the suppression of lung inﬂammation by glucocorticoids, and
therefore provide rationales for effective anti-inﬂammatory therapies.
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A
cute lung injury (ALI) and acute respiratory distress
syndrome (ARDS) are severe inﬂammatory lung diseases
induced by infectious insults. Both syndromes may also
develop as complications of severe trauma or sepsis1. Forty per
cent of septic patients develop ALI, of whom about half die from
inﬂammatory lung diseases2,3. Despite the potent anti-
inﬂammatory effects of glucocorticoids (GCs), their use to treat
or prevent ALI and ARDS is controversially discussed in the
clinic4,5. GC treatment in the early phase of lung inﬂammation
appears to resolve ALI and ARDS6–8. A larger clinical study is
currently trying to determine the parameters for more effective
GC treatment and to develop appropriate guidelines (clinical trial
NCT01731795). One major obstacle facing the use of GCs is the
inadequate understanding of the molecular mechanisms by which
they resolve lung inﬂammation. Therefore, a precise deﬁnition of
the cell type-speciﬁc mode of GC action in the context of ALI is
essential for rational drug design and treatment regimens that
lead to effective resolution of inﬂammation in ALI and ARDS.
GCs act by binding their cognate receptor, the GC receptor
(GR), a member of the nuclear hormone receptor family. As a
monomer, ligand-activated GR represses the activities of pro-
inﬂammatory transcription factors, such as activator protein 1,
nuclear factor kappa B (NF-kB) and interferon regulatory factor
3, by a tethering mechanism called transrepression9,10. On the
other hand, the direct binding of dimerized GR to response
elements in the DNA (GC-response elements) induces gene
transcription, commonly referred to as transactivation. The
prevailing view is that transrepression by the GR monomer is a
major mechanism for inhibiting inﬂammation11. However, it was
recently shown that anti-inﬂammatory responses require not only
gene repression but also gene activation. Indeed, mice with a
point mutation in the GR DNA-binding domain (GRdim) exhibit
less transactivation of GC-induced genes in vivo12 and fail to
resolve inﬂammation in allergic13, autoimmune14 and systemic
inﬂammation15,16. This is partly because of the inability of
GCs to induce anti-inﬂammatory genes, such as dual
speciﬁcity phosphatase 1 (Dusp1; refs 15,17) and annexin A1
(Anxa1; ref. 18). However, the mechanism and the target cells
that mediate the anti-inﬂammatory effects of GCs in lung
inﬂammation are unknown.
A hallmark of ALI is disruption of the endothelial barrier that
facilitates massive inﬁltration of leukocytes into the alveolar
space19. A major regulatory system of endothelial barrier integrity
in the lung is sphingosine kinase 1 (SphK1) and its enzymatic
product, sphingosine 1-phosphate (S1P). The active mediator S1P
is synthesized from sphingosine by SphK1 (ref. 20) and binds to a
family of receptors, of which S1P receptor type 1 (S1PR1) is of
particular importance because it is expressed on endothelial
cells21. S1PR1 triggers Rho family-dependent cytoskeletal
reorganization, leading to enhancement of the barrier function
of the endothelium21. This in turn prevents vascular leakage and
massive inﬁltration in mouse models of ALI22–25.
Here we demonstrate that GCs attenuate inﬂammation in a
murine model of ALI by synergistic upregulation of SphK1 gene
expression in macrophages. This is followed by elevation of
plasma S1P levels, thereby leading to protection of the endothelial
barrier function and to amelioration of the disease.
Results
GCs suppress ALI via the GR dimerization in myeloid cells.
ALI was induced by systemic lipopolysaccharide (LPS) adminis-
tration followed by application of oleic acid (OA; hereafter, co-
treatment with both compounds is designated ‘LPS’). OA was
used as an additional trigger for lung inﬂammation because
naturally occurring serum OA has been shown to be elevated in
samples from sepsis patients at risk of developing lung inﬂam-
mation26,27. The GR agonist dexamethasone (Dex) was applied
during ALI to investigate the anti-inﬂammatory actions of GCs.
LPS treatment resulted in strong lung inﬂammation (Fig. 1) that
was characterized by two features: (i) a strong vascular leakage, as
determined by the accumulation of Evans Blue dye (EB) in lung
tissue (Fig. 1a) and (ii) an enhanced inﬂammatory proﬁle, as
characterized by increased leukocyte inﬁltration into the lung
(Fig. 1b–d). These two features are also hallmarks of human
ALI28–30. It has previously been reported that myeloid cells play
an important role in mediating the anti-inﬂammatory effects of
GCs during sepsis and are critical for survival during
inﬂammation16,17,31. For this reason, myeloid cells might also
be involved in the suppression of ALI by GCs. To test this
hypothesis, Nr3c1tm2GscLyz2tm1(cre)lfo/J (hereafter referred to as
GRLysMCre) mice lacking the GR in myeloid cells were subjected
to ALI in the presence or absence of Dex (Fig. 1a–d). Endothelial
barrier permeability in unchallenged mice, as measured by EB
accumulation, was the same in mutants (GRLysMCre) and
Nr3c1tm2Gsc controls (hereafter referred to as GRﬂox;
Supplementary Fig. 1a), and it was similarly affected by LPS
treatment in both strains (Fig. 1a). Concomitantly, GRLysMCre and
control wild-type (GRﬂox) mice responded to LPS with a strong
cellular inﬁltration and inﬂammation in the lung (Fig. 1b–d).
Treatment of LPS-challenged GRﬂox mice with Dex (LPSþDex)
reduced EB accumulation (Fig. 1a) and decreased leukocyte
inﬁltration (Fig. 1b–d). In contrast to control mice, LPS-
challenged GRLysMCre mice were refractory to Dex treatment.
EB accumulation was not reduced (Fig. 1a), cellular inﬁltration
was persistent (Fig. 1b,c) and bronchoalveolar lavage (BAL) cell
numbers were unaltered (Fig. 1d). Accordingly, the histological
score reﬂecting the severity of ALI32 was reduced after Dex
treatment in GRﬂox control mice but not in GRLysMCre mice
(Fig. 1c). Thus, the GR in myeloid cells is required for the
suppression of ALI pathology by GCs.
GR deﬁciency in GRLysMCre mice affects both macrophages and
neutrophils. To exclude the possibility that the GR in neutrophils
makes a major contribution to lung endothelial stability, GRloxP
mice were crossed with Nr3c1tm2GscTg(Itgax-cre)1-1Reiz (here-
after referred to as CD11cCre) mice33. The resultant GRCD11cCre
mice did not show any recombination of the GRloxP allele in
neutrophils, but there was efﬁcient recombination in blood
monocytes (Supplementary Fig. 1b). Importantly, GRCD11cCre
mice were resistant to Dex treatment during ALI in comparison
with wild-type littermates (GRﬂox) in terms of vascular leakage
(Supplementary Fig. 1c), indicating that loss of the GR in
monocytes (Supplementary Fig. 1b) is sufﬁcient to confer
resistance to Dex treatment in ALI (Supplementary Fig. 1c).
Finally, we tested whether an intact GR dimerization interface is
required for the anti-inﬂammatory activity of GCs during ALI. To
this end, Nr3c1tm3Gsc (hereafter referred to as GRdim) mice were
subjected to ALI and treated with Dex. This treatment failed to
reduce EB accumulation in the lung (Fig. 1e), cellular inﬁltration
(Fig. 1f), the histological score (Fig. 1g) and cell numbers in the
BAL ﬂuid (Fig. 1h) in GRdim mice. The extent of the LPS-induced
lung injury assessed by endothelial permeability, histological
score and cell numbers in the BAL ﬂuid was similar in wild-type
and mutant mice (no signiﬁcant differences; Fig. 1e,g,h). This
implies that a functional GR dimerization interface is required for
the repression of inﬂammation in ALI by GCs.
Of note, absolute numbers (Supplementary Fig. 2) of major
leukocyte subpopulations in the blood were similar in mice of
both genotypes. The only exception was the abundance of
neutrophil granulocytes, which was elevated by Dex application
in wild-type mice, while it was diminished in GRdim mice
(Supplementary Fig. 2a).
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Dex elevates circulating S1P dependent on GR in macrophages.
A primary mechanism of ALI pathogenesis is severe impairment
of endothelial barrier integrity in the lung. A critical role for the
sphingolipid S1P in maintaining lung endothelial barrier function
has been well demonstrated21,34. Consequently, we hypothesized
that plasma S1P levels might be inﬂuenced by Dex treatment in
H
is
to
lo
gi
ca
l s
co
re
0
1
2
3
4
****** **
BA
L 
ce
ll 
nu
m
be
r
(× 
10
6  
pe
r m
l) 
BA
L 
ce
ll 
nu
m
be
r
(× 
10
6  
pe
r m
l) 
0
1
2
3
**
EB
 a
cc
um
ul
at
io
n
(no
rm
ali
ze
d t
o C
o) 
Co LPS
+Dex
LPS Co LPS LPS+DexCo LPS
+Dex
LPS
Co LPSCo LPS
Co LPS+DexLPSCo Co LPS
Co LPSCo LPS Co LPSCo LPS
LPS
+Dex +Dex
Co LPSLPSCo LPSLPS
0
1
2
3
***** **
0
1
2
3
** ***
H&E staining
wt
0
1
2
3
4
*** *
0
1
2
3
* **
H&E staining
EB
 a
cc
um
ul
at
io
n
(no
rm
ali
ze
d t
o C
o) 
H
is
to
lo
gi
ca
l s
co
re
GRflox
GRflox
GRLysMCre
GRflox
GRLysMCre
GRflox
GRLysMCre
GRLysMCre
WT
GRdim
WT
GRdim
WT
GRdim
GRdim
ND
NS
NS
NS NS
*
a b
c d
e f
g h
LPS
+Dex
LPS
+Dex
LPS
+Dex
LPS
+Dex
LPS
+Dex
LPS
+Dex
LPS
+Dex
LPS
+Dex
Figure 1 | GCs inhibit lung inﬂammation by the GR in myeloid cells requiring an intact GR dimerization interface. (a) GRﬂox and GRLysMCre mice were
injected with vehicle (Co), LPS and OA (hereafter, the LPS and OA co-treatment will be designated as ‘LPS’) or LPS and Dex (LPSþDex). After 18 h, EB was
injected i.v., and the mice were killed 30min later. EB accumulation in the lung was determined after perfusion with PBSþ 5mM EDTA. (b) Representative
haematoxylin/eosin (H&E) staining of lung sections (scale bars, 0.1 mm), and (c) histological scores of GRﬂox and GRLysMCre mice treated as described in a.
(d) GRﬂox and GRLysMCre mice were treated as described in a. Cell numbers were determined in the BAL 18 h after the indicated treatments. (e) GRdim and
wild-type (WT) littermate mice were injected with vehicle (Co), LPS or LPSþDex. After 24 h, EB was injected i.v. and 30min later the mice were killed. EB
accumulation in the lung was quantiﬁed as described in a. (f) Representative H&E staining of lung sections (scale bars, 0.1mm) and (g) histological scores
of lungs of littermate WTand GRdim mice from the experiment described in e. (h) GRdim and WTmice were treated as described in e. Cell numbers were
determined in the BAL 24 h after the indicated treatments. Results are presented as mean±s.e.m. Number of biological replicates: (a) (6–10), (c) (18–20),
(d) (7–13), (e) (4–8), (g) (12–16) and (h) (7–11). In a, data are from three independent biological experiments; in c, data are from four independent
biological experiments; in d, data are from two independent biological experiments; in e, data are from two independent biological experiments; in g, data
are from three independent biological experiments out of four; and in h, data are from two independent biological experiments. Statistical analysis was
performed by one-way analysis of variance. *Po0.05, **Po0.01, ***Po0.001; ND, not detectable; NS, not signiﬁcant.
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ALI. No change in circulating S1P levels was detectable in LPS-
induced ALI; however, Dex treatment during ALI signiﬁcantly
increased circulating plasma S1P levels (Supplementary Fig. 1d). In
contrast to their respective control mice in which plasma S1P levels
were increased after treatment of ALI with Dex, mice with an
impaired GR dimerization interface (GRdim; Fig. 2a and
Supplementary Fig. 3a) and mice with deletion of the GR in
myeloid cells (GRLysMCre; Fig. 2b and Supplementary Fig. 3b)
displayed no change in plasma S1P levels. LPS-induced ALI did not
cause a signiﬁcant change in plasma S1P levels between GRLysMCre
mice and littermate control mice (Fig. 2b). We conclude that
GCs elevate plasma S1P levels only if GR dimerization and the GR
in macrophages are intact. Speciﬁc activation of S1PR1 with
SEW2781 strengthened the endothelial barrier in GRLysMCre mice.
SEW2781 was as effective as Dex in reducing EB accumulation in
LPS-challenged wild-type mice, and it rescued the failure of
GRLysMCre mice to respond to Dex’s beneﬁcial effect on endothelial
barrier integrity in the lung (Fig. 2c,d).
Macrophage SphK1 is crucial for anti-inﬂammatory GC actions.
As mice lacking GR expression in macrophages failed to upregulate
S1P levels, we tested the contribution of SphK1 in these cells to S1P
generation and its involvement in the observed anti-inﬂammatory
effects of GCs. To this end, conditional myeloid cell-speciﬁc SphK1
knockout mice (SphK1tm2CghLyz2tm1(cre)lfo/J; hereafter referred to
as SphK1LysMCre) were generated and analysed. In these mice,
expression of SphK1 in isolated macrophages was diminished
(Supplementary Fig. 4a). In contrast, circulating leukocytes were
not altered in SphK1LysMCre mice in comparison with SphK1ﬂox
(SphK1tm2Cgh; hereafter referred to as SphK1ﬂox) controls
(Supplementary Fig. 4b,c).
In SphK1LysMCre mice subjected to ALI, Dex did not increase
circulating S1P levels (Fig. 3a and Supplementary Fig. 3c). This
indicates that myeloid-speciﬁc SphK1 expression is responsible
for the GC-induced increase in S1P levels during ALI. In
accordance, Dex treatment of SphK1LysMCre mice during ALI did
not prevent endothelial leakage, as indicated by EB accumulation
(Fig. 3b,c). Consequently, SphK1LysMCre mice suffered from
persistent inﬂammation and cellular inﬁltration during ALI even
in the presence of Dex (Fig. 3d,e). The extent of the LPS-induced
lung injury assessed by endothelial permeability and cell numbers
in the BAL ﬂuid was similar in wild-type and mutant mice
(no signiﬁcant differences; Fig. 3c,e).
By using the pharmacological SphK1 inhibitor N,N-dimethyl-
sphingosine (DMS), we conﬁrmed that SphK1 is required for the
substantial attenuation of lung inﬂammation by Dex. DMS fully
abrogated the Dex-speciﬁc protective effects on endothelial
barrier integrity and its suppression of cellular inﬁltration
(Supplementary Fig. 4d,e).
Interestingly, we found that the inability of Dex to trigger anti-
inﬂammatory actions in SphK1LysMCre mice was unrelated to
cytokine secretion. Circulating interleukin (IL)-6 plasma levels were
reduced in SphK1LysMCre mice as efﬁciently as in wild-type mice
and LPS-induced injury resulted in a similar IL-6 plasma induction
in both genotypes (Fig. 3f). In line with this observation, IL-1b and
iNOS expression were similarly reduced by Dex treatment in LPS-
stimulated wild-type bone marrow-derived macrophages (BMDMs)
and SphK1-deﬁcient BMDMs (Supplementary Fig. 4f,g).
In conclusion, SphK1 expression in macrophages is a major
mediator of GC effects on the integrity of the endothelial barrier
and cellular inﬁltration, but is dispensable for Dex-mediated
regulation of cytokines.
Dex and pro-inﬂammatory stimuli synergistically induce SphK1.
Having shown that the GR and SphK1 in macrophages are
essential for GC-mediated suppression of ALI, we next investigated
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whether an intact GR dimerization interface regulates SphK1
expression in primary macrophages. LPS treatment alone induced
a twofold increase in SphK1 mRNA irrespective of the genotype.
However, Dex exposure led to rapid upregulation of SphK1 mRNA
in wild-type BMDMs but not in GRdim BMDMs (Fig. 4a). Intri-
guingly, combined treatment with LPS and Dex (LPSþDex) ele-
vated SphK1 mRNA expression even further in wild-type BMDMs
(Fig. 4a). The synergistic increase of SphK1 mRNA levels after this
combined treatment was evident after 1, 4 and 8 h (Fig. 4a and
Supplementary Fig. 5a) and with various LPS/Dex concentrations
(Supplementary Fig. 5b). Moreover, the observed effect was
strongly attenuated in GRdim cells as well as in fetal liver cells
derived from GR knockout macrophages (GRnull), which entirely
lack the GR (Fig. 4a and Supplementary Fig. 5a–c). Synergistic
regulation of SphK1 expression was not observed in endothelial
cells, another potential source of S1P. In both the TC10 cell line
and primary lung endothelial cells, the Dex-induced SphK1 mRNA
expression was not further stimulated by LPS (Supplementary
Fig. 5d,e).
We then tested whether synergistic induction of the SphK1
gene also extends to increased enzymatic activity of SphK1. In
wild-type but not in GRdim BMDMs, enzymatic SphK1 activity
was induced signiﬁcantly more strongly in the combined presence
of LPS and Dex than after separate treatment (Fig. 4b).
Finally, we asked whether the synergistic induction of SphK1
mRNA is restricted to augmenting Dex with LPS, or whether
other strong pro-inﬂammatory triggers might also upregulate
SphK1 expression in concert with Dex. To this end, we treated
BMDMs with Dex and either the toll-like receptor 2 (TLR2)
agonist Pam3CSK4 (Pam; Fig. 4c), the TLR3 agonist polyinosinic-
polycytidylic acid (polyIC; Fig. 4d), or the cytokine tumour-
necrosis factor-a (TNFa; Fig. 4e). In all cases, treatment with
these pro-inﬂammatory triggers combined with Dex led to a
synergistic elevation of SphK1 mRNA expression. Thus, effective
activation of the anti-inﬂammatory SphK1 gene by GCs can be
achieved in concert with TLR2, -3 and -4 activators, as well as
with TNFa, all of which trigger pro-inﬂammatory signalling
pathways.
Synergistic SphK1 induction is dependent on p38 MAPK activity.
As the induction of SphK1 expression requires an intact GR
dimerization interface, we examined the physical presence of the GR
on upstream promoter elements of the SphK1 gene. Using chro-
matin immunoprecipitation (ChIP), we demonstrated direct
b
e
d
f
0
2
4
6
8
**** ***
0
200
400
600
800
1,000 * **
0
20
40
60
80 ***
***
S1
P 
(pm
ol 
ml
–
1 ) 
pla
sm
a
BA
L 
ce
ll 
nu
m
be
r
(× 
10
6  
pe
r m
l) 
SphK1flox
SphK1flox
SphK1LysMCre
SphK1flox
SphK1LysMCre
SphK1flox
SphK1LysMCre
SphK1flox
SphK1LysMCre
SphK1LysMCre
SphK1flox
SphK1LysMCre
IL
-6
 p
la
sm
a 
(ng
 m
l–1
)
c
Evans blue
Histology
0
1
2
3
4
** *
EB
  a
cc
um
ul
at
io
n
(no
rm
ali
ze
d t
o C
o) 
a
NS
LPS+Dex
LPS+Dex
NS
NS
NS
ND ND
NS
NS
LPS LPS
+Dex
LPS LPSCo
LPS LPSCo LPSCoCo
LPS
+Dex
LPS LPS
+Dex
LPSCo Co LPS LPSCo Co
LPS
+Dex
LPS
+Dex
LPS
+Dex
LPS
+Dex
LPS
+Dex
Figure 3 | SphK1 expression in myeloid cells is essential for the anti-inﬂammatory effects of GCs in ALI. (a) SphK1ﬂox and SphK1LysMCre mice were treated
as described in Fig. 1a. The S1P level in plasma (pmolml 1) was determined 24h later by LC/MS/MS. (b) SphK1ﬂox and SphK1LysMCre mice were treated as
described in Fig. 1a, and lung specimens with accumulated EB are shown. (c) EB accumulation of isolated lungs was quantiﬁed as described in Fig. 1a. (d)
Representative haematoxylin/eosin staining of lung sections from SphK1ﬂox and SphK1LysMCre mice treated as described in Fig. 1a (scale bars, 0.1 mm). (e) Cell
numbers were determined in the BAL 24h after the indicated treatments. (f) IL-6 plasma levels (ngml 1) in SphK1ﬂox and SphK1LysMCre mice were
determined by ELISA 5h after LPS or LPSþDex treatment. Results are presented as mean±s.e.m. Number of biological replicates: (a) (8–15), (c) (5–12),
(e) (5–12) and (f) (5–12). In a, c and e, the data are from two independent biological experiments; and in f, the data are from one biological experiment.
Statistical analysis was performed by one-way analysis of variance. *Po0.05, **Po0.01 and ***Po0.001; ND, not detectable; NS, not signiﬁcant.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8796 ARTICLE
NATURE COMMUNICATIONS | 6:7796 | DOI: 10.1038/ncomms8796 | www.nature.com/naturecommunications 5
& 2015 Macmillan Publishers Limited. All rights reserved.
binding of the wild-type GR to a putative GR-binding site of the
SphK1 gene (Fig. 5a and Supplementary Fig. 6a). In contrast, the
GRdim receptor was not recruited to this binding site after treatment
with Dex or LPSþDex (Fig. 5a). Moreover, co-treatment with LPS
and Dex did not further increase GR DNA binding in wild-type
cells relative to Dex alone (Fig. 5a). This suggests that the synergistic
induction of SphK1 mRNA expression by LPS and Dex is instead
related to a regulative effect by LPS.
We therefore tested the involvement of signalling molecules
downstream of the LPS/TLR4 pathway in the synergistic
regulation of SphK1. LPS-induced IkB kinase 2 (IKK-2) signalling
and subsequent NF-kB activation are not involved in SphK1
regulation because treatment with the IKK inhibitor BMS345541
had no effect, and the synergistic induction of SphK1 mRNA was
not affected in BMDMs lacking RelA (Supplementary Fig. 6b,c).
In contrast, we identiﬁed p38 MAPK as an essential component of
the synergistic induction by LPSþDex. Treatment of BMDMs
with the p38 MAPK inhibitor SB203580 strongly interfered with
the synergistic upregulation of SphK1 by LPSþDex at 2 and 4 h
(Fig. 5b and Supplementary Fig. 6d). Contrarily, the p38 MAPK
inhibitor did not interfere with SphK1 mRNA induction by Dex
alone (Fig. 5b and Supplementary Fig. 6d). Accordingly,
synergistic induction of SphK1 by LPSþDex was attenuated in
BMDMs derived from mice with inducible knockout of p38
MAPK (p38aMx1Cre; Fig. 5c). A similar ﬁnding was observed for
the involvement of MSK1, a downstream target of p38 MAPK, in
the regulation of SphK1 expression. Treatment of BMDMs with
the MSK1 inhibitor SB747651A diminished the induction of
SphK1 mRNA by LPSþDex (Fig. 5d). To obtain additional
insight into the mechanism of synergistic SphK1 induction by
LPSþDex, we used the Phospho Explorer Antibody Array as a
means of identifying direct or indirect MSK1 downstream targets.
BMDMs were treated with or without SB747651A, stimulated with
LPSþDex and subsequently analysed concerning the protein
phosphorylation status. Using this method, we identiﬁed 16 top
candidate proteins with decreased phosphorylation upon MSK1
inhibition in LPSþDex-stimulated BMDMs, which might
represent direct or indirect downstream targets (Table 1).
Strikingly, a number of these targets interact with Src signalling,
which may be a regulator of the cooperative LPS and Dex
signalling (Fig. 5e). Taken together, the results show that LPS-
induced p38 MAPK and MSK1 trigger a signalling network
cooperate with the dimerized GR to synergistically induce SphK1
gene expression (Fig. 6).
Discussion
Treatment of ALI with GCs is highly debated because of
conﬂicting data emerging from clinical studies and trials4,35.
Delayed initiation of high-dose GC treatment may be detrimental
because of the occurrence of muscle weakness and the possibility
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of severe secondary infections3,8. In contrast, GC treatment during
the early exudative phase of ALI might be beneﬁcial because it can
resolve the acute phase of lung inﬂammation6–8. We present here,
for the ﬁrst time, the molecular mechanism of the anti-
inﬂammatory effects of GCs during the early phase of ALI.
We have identiﬁed a novel mechanism by which GCs interfere
with the pathogenesis of ALI, involving increased SphK1 gene
expression and S1P production. The SphK1–S1P–S1PR1 axis is
recognized as an important regulator of endothelial barrier
integrity that prevents lung inﬂammation by binding S1P to
S1PR1 on lung endothelial cells21–23,36,37. We provide evidence
that GR-dependent SphK1 expression in myeloid cells,
particularly macrophages, is responsible for the elevated levels
of S1P in plasma and the subsequent suppression of ALI. First,
neither GRLysMCre nor GRdim mice had increased circulating S1P
plasma levels after GC treatment, which correlates with the
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inability of Dex to suppress vascular leakage in the lungs of these
two mouse strains. The Dex response was also attenuated in
GRCD11cCre mice, in which GR expression in neutrophils is
retained. Hence, the GR in the monocyte/macrophage cell lineage
is required for its anti-inﬂammatory effects. Second, in animals
with ALI, treatment with the S1PR1 agonist SEW2781 or with
Dex prevented vascular leakage to similar degrees. Indeed,
SEW2781 even rescued vascular leakage in GRLysMCre mice,
which are refractory to Dex. Third, pharmacological inhibition of
SphK1 in wild-type mice by co-treatment with DMS completely
abrogated the inhibition of vascular leakage and suppression of
inﬂammation by Dex. Finally, ablation of the SphK1 gene in the
myeloid lineage abolished the elevation of plasma S1P levels by
Dex and eliminated any effects of GCs on vascular leakage and
inﬂammation. In addition to macrophages, other sources of S1P
production are known, such as red blood cells thrombocytes and
endothelial cells38. Hence, it is likely that these cells also
contribute to the basal plasma levels of S1P. Accordingly, we
detected induction of SphK1 in endothelial cells by Dex; however,
synergistic regulation by LPS and Dex was not observed.
Although we cannot entirely exclude a contribution from
endothelial cells to Dex-regulated S1P plasma levels, the lack of
S1P induction in Dex-exposed myeloid-speciﬁc GR and SphK1
mutant mice strongly indicates that macrophages make a major
contribution to this GC effect.
Our data support the concept that SphK1 expression and hence
S1P production are induced by GCs under inﬂammatory
conditions and are required for the anti-inﬂammatory actions of
GCs. Despite earlier reports suggesting that SphK1 has a pro-
inﬂammatory role39,40 recent evidence afﬁrms a major anti-
inﬂammatory function of SphK1 (ref. 41). Speciﬁcally, mice with
complete deletion of SphK1 (SphK1 / ) are highly susceptible to
LPS-induced ALI and exhibit increased lung vascular leakage. This
suggests that the SphK1 function is essential for protection from
lung injury. Accordingly, viral SphK1 overexpression protects
these mice from LPS-induced ALI41. Moreover, S1P has recently
been shown to mediate anti-inﬂammatory effects in chronic
inﬂammatory diseases as well, such as psoriasis42. In addition,
patients with multiple sclerosis have been efﬁciently treated with
FTY720, an S1P analogue43,44. An ongoing clinical trial is
investigating the effects of FTY720 on lung function
(NCT00416845), which highlights the importance of our attempt
to identify the molecular mechanism that stabilizes the SphK1–
S1P–S1PR1 axis. We demonstrate that SphK1 expression in
macrophages is sufﬁcient to protect against ALI without having
any effect on the composition of leukocyte subpopulations, plasma
cytokines and BMDM cytokine mRNA expression. This is in
agreement with the ﬁndings of Xiong et al.45. Strikingly, we
observed that Dex efﬁciently represses cytokine secretion in
SphK1LysMCre mice, indicating that cytokine repression is not
sufﬁcient to resolve inﬂammation. Our results prove that the
SphK1–S1P axis plays an essential role in attenuating lung
inﬂammation by GCs. Moreover, we provide evidence that
reducing the expression of pro-inﬂammatory cytokines, a classic
feature of Dex treatment, is not sufﬁcient to resolve ALI. Finally,
we show that the abundance of individual leukocyte subsets in the
blood was largely similar in wild-type and GRdim mice, albeit the
latter ones are refractory to Dex treatment. The sole difference we
observed was that Dex increased the number of neutrophil
granulocytes only in the blood of wild-type and not of GRdim mice.
Table 1 | Downregulation of phosphorylation of distinct
proteins after LPSþDex treatment and MSK1 inhibition
determined by phospho-array.
Gene
name
Target Phospho-
expression
Fold
change
Ccnd3 Cyclin D3 (p-Thr283) Down 0.694
Crk CrkII (p-Tyr221) Down 0.681
Hdac1 HDA C1 (p-Ser421) Down 0.545
Hsp90ab1 HSP90B (p-Ser226) Down 0.664
Hspb2 HSP27 (p-Ser82) Down 0.723
Kdr VEGFR2 (p-Tyr951) Down 0.613
Lyn LYN (p-Tyr507) Down 0.674
Nf2 Merlin (p-Ser10) Down 0.557
Raf1 Raf1 (p-Ser259; p-Ser289) Down 0.404
Rps6ka1 P90RSK (p-Thr359/Ser363;
p-Thr573)
Down 0.626
Rps6ka5 MSK1 (p-Ser360) Down 0.730
Src Src (p-Tyr529) Down 0.641
Syk SYK (p-Tyr525) Down 0.697
Ywhaz 14-3-3 zeta (p-Ser58) Down 0.720
Pgr Progesterone receptor (A b-190) Down 0.756
Krt18 Keratin 18 (A b-52) Down 0.779
Jun c-Jun (A b-93) Down 0.781
BMDMs, bone marrow-derived macrophages; Dex, dexamethasone; LPS, lipopolysaccharide.
BMDMs were pretreated for 60min with and without 10mM SB747651A, and then treated with
LPSþDex for 4 h, and changes in protein phosphorylation events were measured with the
Phospho Explorer Antibody Array (Full Moon BioSystems). The table lists proteins where the
expression of protein phosphorylation was downregulated after MSK1 inhibition. The fold change
indicates the change of downregulation.
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Granulocytosis after GC therapy is a well-known phenomenon
and has been assigned to the demargination of these cells from the
blood vessels endothelium46. As we could show that direct effects
of GCs on neutrophils were not involved in the suppression of
ALI, it is possible that changes in endothelial cells induced by
increased S1P plasma levels may be responsible for the
granulocytosis observed in wild-type mice only. Collectively,
these ﬁndings indicate that modulation of the immune system
by GCs does not contribute to the resolution of lung inﬂammation.
It has been reported that LPS47,48 and Dex alone49,50can
induce SphK1 mRNA expression. However, combined treatment
with LPS and Dex—which mimics exposure to GCs during
inﬂammatory conditions—led to a strong synergistic
upregulation of SphK1 mRNA expression. This strong
induction was seen in primary BMDMs and was dependent on
an intact GR dimerization interface. Hence, the wild-type GR but
not the mutant GRdim receptor is recruited to the SphK1 gene
after Dex and LPSþDex treatment; however, as recently shown,
the GRdim can still bind preferentially as a monomer to some sites
compromising the GR cistromes51. Interestingly, the synergistic
regulation appears to be restricted to macrophages, as we did not
observe a similar effect in endothelial cells, where Dex-stimulated
SphK1 expression independently of LPS. Furthermore, we
demonstrate for the ﬁrst time that the synergistic action by
pro-inﬂammatory stimuli and Dex on SphK1 mRNA
upregulation occurs through a number of TLR ligands and is
not restricted to TLR4 stimulation by LPS. Namely, TNFa, TLR1/
2 and TLR3 agonists potently increased SphK1 mRNA levels in
combination with Dex exposure in a manner similar to that of
LPS. Moreover, our report of synergistic gene regulation being an
anti-inﬂammatory mechanism is in line with the recent ﬁnding
that the MAPK phosphatase DUSP1 is cooperatively induced by
IL-1b and Dex in human pulmonary epithelial A549 cells52.
Our efforts to dissect the signalling pathways involved in the
synergy between LPS and GCs revealed that NF-kB signalling was
dispensable, whereas the p38 MAPK–MSK1 signalling axis was
essential. In view of the established pro-inﬂammatory role of p38
(ref. 53), it might be considered counter-intuitive that synergy is
required between p38 and the anti-inﬂammatory actions of GCs to
mediate the upregulation of SphK1. In certain inﬂammatory
models, p38 has been assumed to be a direct target of GC-induced
DUSP1, resulting in the dampening of inﬂammation17. However,
more recently, an anti-inﬂammatory function of p38 has also been
demonstrated in some types of inﬂammation. This is illustrated by
the worsened arthritis in mice with conditional deletion of p38 in
myeloid cells54. Strikingly, in a mouse lung injury model, a p38
inhibitor failed to attenuate inﬂammation55. This is in line with
our data that support the concept that p38 activation may
contribute to the anti-inﬂammatory actions of GCs in ALI. An
obvious candidate p38 target leading to SphK1 induction is MSK1,
a kinase that phosphorylates many transcription factors and
chromatin components56. The direct substrate of MSK1 involved
in SphK1 regulation is unknown. Potential MSK1 downstream
targets that might mediate the synergistic induction of SphK1 by
LPSþDex were identiﬁed by using the Phospho Explorer
Antibody Array. Notably, one of the 16 top proteins showing
decreased phosphorylation upon MSK1 inhibition and LPSþDex
stimulation is Src. We consider this protein to be a highly
promising candidate as it has been shown to mediate HuR
phosphorylation and hence stabilize SphK1 mRNA57, and is at the
centre of the identiﬁed signalling network (Fig. 5e). Further
investigation is required to fully understand SphK1 induction, for
instance, to determine whether particular transcription factors
are involved, for example, the GR itself58,59, or whether
decondensation of chromatin occurs at the promoter of the
SphK1 gene to enhance accessibility for transcription factors.
Our results support the use of corticosteroids to activate the
GR-coordinated SphK1–S1P–S1PR1 axis as an efﬁcient treatment
regimen in the early states of ALI. Furthermore, strengthening the
SphK1–S1P–S1PR1 axis in combination with GC application
might become a novel strategy for ALI therapy, and thereby
enhance the efﬁcacy of short-range GC treatment in septic
patients since 40% of them develop ALI. Indeed, in recent studies,
S1PRs were considered as potential biomarkers for the grade of
lung inﬂammation60,61. Finally, the S1P analogue FTY720 is
already in use for the treatment of multiple sclerosis43,44, and
there are currently clinical trials studying the effects of FTY720
on lung function (NCT00416845). Furthermore, the use of
Dex to treat lung inﬂammation is already at the clinical trial
stage (NCT01731795), highlighting the importance of our
ﬁndings on SphK1 as a new GC-induced gene. Taken together,
our ﬁndings suggest that targeting lung vascular stability
mediated by p38–MSK1 signalling and the SphK1–S1P–S1PR1
axis might represent a new strategy for the treatment of lung
inﬂammation.
In conclusion, our study provides novel insights into GC action
that may pave the way for improved anti-inﬂammatory therapy
of ALI.
Methods
Mice. GRdim mice62 were backcrossed for at least ﬁve generations to the FVB/N
background. GRLysMCre mice16 were backcrossed for at least ﬁve generations to the
BALB/c or C57BL/6 background. SphK1LysMCre C57BL/6 mice were bred by
Thorsten Schinke (Universita¨tsklinikum Hamburg-Eppendorf (UKE), Hamburg,
Germany) and the SphK1ﬂox mice were generated and kindly provided by Shaun R.
Coughlin (University of California San Fransisco (UCSF), CA, USA). Mx1-cre
p38aﬂox mice have previously been described63,64. To induce deletion of the ﬂoxed
alleles in Mx1-cre p38aﬂox mice, they were injected intraperitoneally (i.p.) with
polyIC (13mg kg 1 body weight, three times every 48 h). The mice were kept
under pathogen-free conditions. Male and female mice at the age of 9–14 weeks
were used.
Nomenclature for the used mouse strains:
GRﬂox (Nr3c1tm2Gsc), GRLysMCre (Nr3c1tm2GscLyz2tm1(cre)lfo/J),
GRCD11cCre (Nr3c1tm2GscTg(Itgax-cre)1-1Reiz), GRdim (Nr3c1tm3Gsc), SphK1ﬂox
(SphK1tm2Cgh), SphK1LysMCre (SphK1tm2CghLyz2tm1(cre)lfo/J).
ALI and analysis. LPS was applied i.p. and OA was applied intravenously (i.v.).
Male and female mice at the age of 9–14 weeks were injected i.p. with 10mg kg 1
body weight LPS (Sigma, L2880), and 30min later i.v. with 2.6 ml g 1 body
weight OA (Sigma, O1008). OA was prepared as a 4% solution in 0.1% BSA65.
Dex (1.25mg kg 1 body weight; Sigma, D2915) was applied intranasally
simultaneously with i.p. injection of LPS. For SphK1 inhibition, mice were injected
i.v. with 200 mM DMS (Biomol) as previously described66. S1PR1 agonist SEW2781
(Cayman) was injected i.v. (0.3mg kg 1 body weight) as previously described67.
Mice were killed after 18–24 h, and lungs were prepared for BAL, EB extraction or
histology.
Immediately after killing the mice, BAL was collected by tracheal cannulation
using 1ml of cold PBS and then centrifuged (300g, 15min, 4 C). Following
resuspension of the pellet and lysis of erythrocytes, total cell numbers were
determined by automatic counting (Casy counter, Scha¨rfe).
Pulmonary microvascular permeability was determined by accumulation of EB
dye (Sigma, E2129). EB dye (25mg kg 1 body weight) was injected i.v. 30min
before killing. Following killing, the mice were perfused by right ventricle puncture
with ice-cold PBSþ 5mM EDTA. Lungs were removed and photographed, and EB
dye was extracted in formamide (4ml g 1) at 60 C overnight. The supernatant
was separated by centrifugation at 5,000g for 30min at room temperature, and
absorbance was measured by spectrophotometry at a wavelength of 620 nm
(Mithras LB940, Berthold Technologies).
For histological analysis, lungs were perfused with PBSþ 5mM EDTA and
ﬁxed in 4% formaldehyde in 0.1M phosphate buffer (pH 7.2). Within 24 h, lungs
were embedded in parafﬁn and 4-mm-thick sections were stained with
haematoxylin/eosin. The histopathology of the lung injury was scored
quantitatively as previously described32. The score is based on the following
features: structure of the alveolar septae (thin or congested); intra-alveolar
haemorrhage or ﬁbrin; cell inﬁltrates (in septae, alveolar lumen, pleura and
bronchi)32. Lung injury was characterized by patchy areas. Histological scoring was
performed blindly. Inﬂammation was graded from 0 to 3, and other parameters of
inﬂammation (vessel, pleura and bronchus) were evaluated. The average score was
calculated as previously described in ref. 32.
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Extraction and quantiﬁcation of S1P. S1P of mouse plasma was determined by
liquid chromatography coupled to triple-quadrupole mass spectrometry (LC/MS/
MS)68. Positive electrospray ionization LC/MS/MS analysis was used for detection
of all analytes. Multiple reaction monitoring transitions were as follows: S1P m/z
380/264, C17-S1P m/z 366/250, sphingosine m/z 300/282, C17-sphingosine m/z
286/268 and sphingosine-D7 m/z 307/289. Liquid chromatographic resolution of all
analytes was achieved using a 2 60mm MultoHigh C18 reversed-phase column
with 3mm particle size (CS-Chromatographie Service). Standard curves were
generated by adding increasing concentrations of the analytes to 300 pmol of the
internal standards C17-sphingosine and C17-S1P or deuterated sphingosine-D7.
Linearity of the standard curves and correlation coefﬁcients were obtained by linear
regression analyses. Data analysis was performed using Analyst 1.4 (AB Sciex).
Cell culture and quantitative RT–PCR. BMDMs were obtained from wild-type
and GRdim mice as previously described16. BMDMs were treated with LPS
(100 ngml 1) and Dex (10 6M) for the indicated durations. RNA isolation and
quantitative RT–PCR analysis were performed as previously described16. The
primers used for RT–PCR were SphK1 50-CCAAGTGCACCCAAACTACC-30 and
SphK1 30-GCCCCACCTTCTAGCTTTCT-50 . For inhibition experiments, BMDMs
were pretreated for 30min with 10 mM SB203580 (Sigma, S8307), a p38 MAPK
pathway inhibitor; 10min pretreated with 8 mM BMS345541 (Calbiochem), an
IKKb inhibitor; or 60min pretreated with 10 mM SB747651A (Axon-Medchem), an
MSK1 inhibitor. The cells were subsequently stimulated with LPS, Dex or
LPSþDex for the indicated durations. TNFa (500 units per ml; a gift from Claude
Libert, VIB/University of Ghent, Belgium), Pam3CSK4 (200 ngml 1; Invivogen),
or polyIC (50 ngml 1) was used either in a single treatment or together with Dex
(10 6M) to stimulate BMDMs for the indicated durations. RNA isolation and
quantitative RT–PCR analysis were performed as previously described16. SphK1
activity in BMDMs was measured from the conversion of C17- and C18-
sphingosine to S1P by LC/MS/MS as outlined above (Extraction and quantiﬁcation
of S1P) and as previously described69. The endothelial cell line TC10 was a gift
from Claude Libert, VIB/University of Ghent, Belgium. Primary lung endothelial
cells were obtained from Cell Biologics.
Chromatin immunoprecipitation. ChIP analysis of wild-type and GRdim BMDMs
was performed 4 h after stimulation with LPS (100 ngml 1) and Dex (10 6M).
ChIP assays were performed as described elsewhere70. The anti-GR antibody
(sc-8992) was obtained from Santa Cruz Biotechnology. The following primers
were used: SphK1 forward 50-GCTGCTGATGTGAAGGATAC-30 and SphK1
reverse 50-GCTGCTGATGTGAAGGATAC-30 . Foxl2 was selected as a negative
control and the following primers were used: forward 50-GCTGGCAGAATAGCA
TCCG-30 and reverse 50-TGATGAAGCACTCGTTGAGGC-50. The fold
enrichment over immunoglobulin G was calculated. Putative GC-response
element-binding sites were identiﬁed by Genomatix software.
Flow cytometric analysis and sorting. Blood samples were obtained by cardiac
puncture. A 100-ml aliquot of blood was collected into 900 ml Alsever’s solution and
then centrifuged at 350g for 10min at 4 C. The supernatant was removed, the cells
were treated twice with erythrocyte lysis buffer, washed with 0.1% BSA in PBS and
then resuspended in the reﬂux. Cell counts were determined with the aid of a
Neubauer haemocytometer.
For ﬂow cytometric analysis, Fc receptor blockade was performed by incubation
with TruStain fcX (anti-mouse CD16/32; clone: 93; cat. no. 101320; 1:2,000).
Subsequently, the cells were stained with the following monoclonal antibodies:
PerCP/Cy5.5 anti-mouse CD3 (clone: 17A2; cat. no. 100218; 1:500), APC anti-
mouse/human CD45R/B220 (clone: RA3-6B2; cat. no. 103212; 1:800), PE anti-
mouse CD49b (clone: DX5; cat. no. 108908; 1:400), FITC anti-mouse F4/80 (clone:
BM8; cat. no. 123108; 1:500), APC/Cy7 anti-mouse Ly-6G/Ly-6C (Gr-1; clone:
RB6-8C5; cat. no. 108424; 1:2000), PE/Cy7 anti-mouse CD11c (cat. no. 117318;
1:500), PE anti-mouse CD115 (cat. no. 135505; 1:500). All the antibodies were
obtained from BioLegend (Uithoorn, The Netherlands). Data were acquired on a
BD FACS Canto II ﬂow cytometer (BD Biosciences) and were analysed using
FlowJo software (Tree Star).
Protein phosphorylation proﬁling. Hybridization and analysis of the Phospho
Explorer Antibody Array were carried out by Full Moon BioSystems (Sunnyvale,
CA, USA) and served to survey the phosphorylation state of select proteins. The
assay was performed using BMDMs pretreated for 60min with 10 mM SB747651A,
followed by LPSþDex for 4 h. At the end of the incubation time, proteins were
collected and analysed. Physical and functional association among the down-
regulated genes after MSK1 inhibition was done by using the STRING 10.1 data-
base and the network was visualized using Cytoscape 3.1.0.
Statistics. Results are presented as mean±s.e.m. Statistical analyses were per-
formed with one-way analysis of variance (ANOVA) for comparison, followed by
Tukey’s post hoc within one group. For the comparison of two groups (genotypes),
one-way analysis of variance followed by Tukey’s post hoc test for multiple com-
parisons was performed. Statistical analyses were performed using the GraphPad
Prism software (GraphPad Software) and sample size was chosen with G*Power3.1
(University Du¨sseldorf). Outlying sample exclusion criteria were done with
GraphPad Prism Outlier Calculator. Data were considered statistically signiﬁcant:
*Po0.05, **Po0.01 and ***Po0.001.
Declaration of approval for animal experiments. All experiments involving
animals were approved by the Thu¨ringer Landesamt fu¨r Lebensmittelsicherheit
und Verbraucherschutz (TLLV) and Regierungspra¨sidium Tu¨bingen.
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